Novare Capital Management’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$13.3M Sell
110,477
-2,629
-2% -$304K 1.05% 28
2025
Q4
$11.9M Buy
113,106
+1,322
+1% +$124K 0.89% 37
2025
Q3
$9.38M Sell
111,784
-8,480
-7% -$698K 0.71% 52
2025
Q2
$9.52M Sell
120,264
-76,476
-39% -$6.08M 0.77% 48
2025
Q1
$17.7M Buy
196,740
+2,128
+1% +$199K 1.54% 19
2024
Q4
$19.4M Buy
194,612
+6,447
+3% +$665K 1.63% 17
2024
Q3
$21.4M Buy
188,165
+22,077
+13% +$2.62M 1.81% 13
2024
Q2
$20.6M Sell
166,088
-4,031
-2% -$519K 1.85% 12
2024
Q1
$22.4M Buy
170,119
+7,656
+5% +$944K 2.03% 12
2023
Q4
$17.7M Buy
162,463
+7,608
+5% +$790K 1.8% 14
2023
Q3
$15.9M Buy
154,855
+5,960
+4% +$642K 1.8% 12
2023
Q2
$17.2M Sell
148,895
-1,102
-0.7% -$125K 1.85% 11
2023
Q1
$16M Sell
149,997
-18,884
-11% -$2.04M 1.81% 10
2022
Q4
$18.7M Sell
168,881
-5,385
-3% -$550K 2.21% 7
2022
Q3
$15M Buy
174,266
+12,517
+8% +$1.12M 1.92% 9
2022
Q2
$14.7M Buy
161,749
+55,123
+52% +$4.89M 1.82% 10
2022
Q1
$8.75M Buy
106,626
+4,448
+4% +$351K 0.93% 42
2021
Q4
$7.83M Buy
102,178
+2,903
+3% +$231K 0.79% 58
2021
Q3
$7.46M Buy
99,275
+5,430
+6% +$413K 0.83% 57
2021
Q2
$7.3M Buy
93,845
+89,294
+1,962% +$6.64M 0.82% 61
2021
Q1
$335K Sell
4,551
-311
-6% -$22.9K 0.04% 117
2020
Q4
$379K Sell
4,862
-99
-2% -$7.57K 0.05% 107
2020
Q3
$393K Buy
4,961
+348
+8% +$27.3K 0.06% 108
2020
Q2
$340K Sell
4,613
-1,228
-21% -$92.4K 0.05% 113
2020
Q1
$429K Buy
5,841
+1,237
+27% +$97.2K 0.08% 110
2019
Q4
$400K Buy
4,604
+1,093
+31% +$89.8K 0.06% 124
2019
Q3
$282K Buy
3,511
+48
+1% +$3.85K 0.04% 128
2019
Q2
$277K Hold
3,463
0.04% 125
2019
Q1
$275K Sell
3,463
-62
-2% -$4.64K 0.04% 127
2018
Q4
$257K Buy
3,525
+1
+0% +$71 0.05% 130
2018
Q3
$239K Sell
3,524
-106
-3% -$6.75K 0.04% 137
2018
Q2
$210K Sell
3,630
-2,685
-43% -$151K 0.04% 148
2018
Q1
$328K Sell
6,315
-68
-1% -$3.67K 0.06% 130
2017
Q4
$343K Buy
6,383
+136
+2% +$7.54K 0.06% 127
2017
Q3
$382K Buy
6,247
+2,104
+51% +$128K 0.07% 129
2017
Q2
$253K Sell
4,143
-4,291
-51% -$261K 0.06% 107
2017
Q1
$511K Sell
8,434
-289
-3% -$17.5K 0.12% 92
2016
Q4
$490K Buy
8,723
+152
+2% +$8.9K 0.12% 90
2016
Q3
$510K Buy
8,571
+3,793
+79% +$222K 0.13% 90
2016
Q2
$263K Sell
4,778
-5,054
-51% -$269K 0.07% 99
2016
Q1
$496K Sell
9,832
-929
-9% -$45.5K 0.14% 90
2015
Q4
$542K Sell
10,761
-711
-6% -$35.8K 0.15% 92
2015
Q3
$541K Buy
11,472
+7,103
+163% +$377K 0.15% 90
2015
Q2
$237K Sell
4,369
-1,168
-21% -$65.5K 0.06% 101
2015
Q1
$304K Buy
5,537
+91
+2% +$5.15K 0.08% 99
2014
Q4
$295K Sell
5,446
-34
-0.6% -$1.89K 0.07% 101
2014
Q3
$310K Buy
5,480
+210
+4% +$11.8K 0.08% 106
2014
Q2
$291K Buy
5,270
+406
+8% +$22.1K 0.07% 110
2014
Q1
$263K Buy
4,864
+518
+12% +$26.8K 0.07% 109
2013
Q4
$208K Buy
+4,346
New +$199K 0.06% 118

Other funds holding MRK

Novare Capital Management's MRK Position: Q1 2026 in Review

Novare Capital Management reduced its Merck (MRK) stake by 2.3% in Q1 2026, selling an estimated $304K and leaving 110,477 shares worth $13.3M. The position accounts for 1.05% of the portfolio, ranked #28.

Novare Capital Management first reported a position in MRK in Q4 2013 and has held it in 50 quarters since. The position peaked at $22.4M in Q1 2024. 3,779 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Novare Capital Management held 110,477 shares of Merck worth $13.3M as of Q1 2026.
  • Novare Capital Management sold 2,629 Merck shares in Q1 2026, an estimated $304K.
  • Merck made up 1.05% of Novare Capital Management's portfolio in Q1 2026, its #28 holding.
  • Novare Capital Management first reported a position in Merck in Q4 2013 and has held it in 50 quarters since.
  • Novare Capital Management's Merck position peaked at $22.4M in Q1 2024.
  • 3,779 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Novare Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.